Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2016 Nov 2

PMID 27754602

Citations 6

Authors

Y K Lyauk

C Stage

T K Bergmann

L Ferrero-Milliani

D Bjerre

R Thomsen

K P Dalhoff

H B Rasmussen

G Jurgens

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to identify demographic and genetic factors that significantly affect methylphenidate (MPH) pharmacokinetics (PK), and may help explain interindividual variability and further increase the safety of MPH. d-MPH plasma concentrations, demographic covariates, and carboxylesterase 1 (CES1) genotypes were gathered from 122 healthy adults and analyzed using nonlinear mixed effects modeling. The structural model that best described the data was a two-compartment disposition model with absorption transit compartments. Novel effects of rs115629050 and CES1 diplotypes, as well as previously reported effects of rs71647871 and body weight, were included in the final model. Assessment of the independent and combined effect of CES1 covariates identified several specific risk factors that may result in severely increased d-MPH plasma exposure.

Citing Articles

Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.

Liu Y, Li J, Zhu H Expert Opin Drug Metab Toxicol. 2024; 20(5):377-397.

PMID: 38706437 PMC: 11151177. DOI: 10.1080/17425255.2024.2348491.

A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and extended-release capsule.

Gupta P, Incledon B, Gobburu J, Gomeni R CPT Pharmacometrics Syst Pharmacol. 2023; 13(1):132-142.

PMID: 37864318 PMC: 10787209. DOI: 10.1002/psp4.13067.

The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.

Brown J Methods Mol Biol. 2022; 2547:427-436.

PMID: 36068472 DOI: 10.1007/978-1-0716-2573-6_15.

Stability of Methylphenidate under Various pH Conditions in the Presence or Absence of Gut Microbiota.

Aresti-Sanz J, Schwalbe M, Pereira R, Permentier H, El Aidy S Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451830 PMC: 8398889. DOI: 10.3390/ph14080733.

Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.

Patrick K, Rodriguez W Drug Metab Dispos. 2019; 47(7):764-767.

PMID: 31028056 PMC: 6584788. DOI: 10.1124/dmd.119.087189.

References

Tarkiainen E, Backman J, Neuvonen M, Neuvonen P, Schwab M, Niemi M . Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. 2012; 92(1):68-71. DOI: 10.1038/clpt.2012.13. View

Nissen S . ADHD drugs and cardiovascular risk. N Engl J Med. 2006; 354(14):1445-8. DOI: 10.1056/NEJMp068049. View

Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M . Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009; 57(7-8):731-3. DOI: 10.1016/j.neuropharm.2009.08.014. View

Faraj B, Israili Z, Perel J, Jenkins M, Holtzman S, CUCINELL S . Metabolism and disposition of methylphenidate-14C: studies in man and animals. J Pharmacol Exp Ther. 1974; 191(3):535-47. View

Zhu H, Patrick K, Yuan H, Wang J, Donovan J, Devane C . Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008; 82(6):1241-8. PMC: 2427248. DOI: 10.1016/j.ajhg.2008.04.015. View

Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, Aoki Y . Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics. 2008; 18(10):911-20. DOI: 10.1097/FPC.0b013e32830b0c5e. View

Tessier A, Bertrand J, Chenel M, Comets E . Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates. AAPS J. 2015; 17(3):597-608. PMC: 4406951. DOI: 10.1208/s12248-015-9726-8. View

Sun Z, Murry D, Sanghani S, Davis W, Kedishvili N, Zou Q . Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004; 310(2):469-76. DOI: 10.1124/jpet.104.067116. View

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T . A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 59(9):829-35. DOI: 10.1016/j.biopsych.2005.09.011. View

10.

Volkow N, Wang G, Fowler J, Molina P, Logan J, Gatley S . Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl). 2003; 166(3):264-70. DOI: 10.1007/s00213-002-1340-7. View

11.

Morton W, Stockton G . Methylphenidate Abuse and Psychiatric Side Effects. Prim Care Companion J Clin Psychiatry. 2004; 2(5):159-164. PMC: 181133. DOI: 10.4088/pcc.v02n0502. View

12.

Treceno C, Martin Arias L, Sainz M, Salado I, Ortega P, Velasco V . Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf. 2012; 21(4):435-41. DOI: 10.1002/pds.2348. View

13.

Keizer R, Zandvliet A, Beijnen J, Schellens J, Huitema A . Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. AAPS J. 2012; 14(3):601-11. PMC: 3385822. DOI: 10.1208/s12248-012-9373-2. View

14.

Hardy S . Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother. 2009; 7(1):34-59. PMC: 2738590. DOI: 10.1016/j.amjopharm.2009.02.006. View

15.

Teuscher N, Adjei A, Findling R, Greenhill L, Kupper R, Wigal S . Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. Drug Des Devel Ther. 2015; 9:2767-75. PMC: 4454220. DOI: 10.2147/DDDT.S83234. View

16.

Kerr C, Drake J, Milch R, Brazeau D, Skretny J, Brazeau G . Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 2012; 43(1):68-77. DOI: 10.1016/j.jpainsymman.2011.03.026. View

17.

Kimko H, Cross J, Abernethy D . Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 2000; 37(6):457-70. DOI: 10.2165/00003088-199937060-00002. View

18.

Wang X, Wang G, Shi J, Aa J, Comas R, Liang Y . CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J. 2015; 16(3):220-30. PMC: 6329299. DOI: 10.1038/tpj.2015.42. View

19.

Schelleman H, Bilker W, Kimmel S, Daniel G, Newcomb C, Guevara J . Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012; 169(2):178-85. DOI: 10.1176/appi.ajp.2011.11010125. View

20.

Thorpy M . Update on therapy for narcolepsy. Curr Treat Options Neurol. 2015; 17(5):347. DOI: 10.1007/s11940-015-0347-4. View